TrialJournal for immunotherapy of cancer2020

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors.

Coya Tapia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.